Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.
Schupbach, Michael MD 1,2,3; Lohmann, Ebba MD 3,4; Anheim, Mathieu MD 5; Lesage, Suzanne PhD 3,6; Czernecki, Virginie MA 1,2; Yaici, Sadek MD 1,2; Worbe, Yulia MD 1,3; Charles, Perrine MD, PhD 1,2,3,4; Welter, Marie-Laure MD 1,2,3; Pollak, Pierre MD, PhD 5; Durr, Alexandra MD, PhD 3,4,6; Agid, Yves MD, PhD 1,2,3,6; Brice, Alexis MD 2,3,4,6,*
[Report] Movement Disorders. 22(1):119-122, January 2007.

(Format: HTML, PDF)

colon; Stimulation of the subthalamic nucleus (STN) improves motor signs in patients with levodopa-responsive Parkinson's disease (PD). Mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause Parkinsonism. We assessed 69 patients under STN stimulation and found heterozygous LRRK2 mutations in 9 (G2019S in 8 and T2031S in 1). The age at onset of PD, the clinical characteristics before or after neurosurgery, and the clinical response to STN stimulation were similar in both groups. Two patients with the G2019S LRRK2 mutation still benefited from STN stimulation, 9 and 10 years after surgery. Patients with LRRK2 mutations are, therefore, good candidates for STN stimulation.

Copyright (C) 2007 John Wiley & Sons, Inc.